From Aurinia Pharmaceuticals's results release of 2026年10月30日; its quarterly report has since been filed.

• Revenue

  Actual

  US$83.7M

  +14% y/y ↑
  +0.6% q/q ↑

  Guided

  —

  No guide given

• EPS, GAAP

  Actual

  US$0.23

  0.0% y/y →
  -18% q/q ↓

  Guided

  —

  No guide given

• Operating income, GAAP

  Actual

  US$35.4M

  +19% y/y ↑
  -24% q/q ↓

  Guided

  —

  No guide given

Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.